Novel pharmacologic therapies for cystic fibrosis

Journal of Clinical Investigation

Volumn 103, Issue 4, 1999, Pages 447-452

  Zeitlin, Pamela L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC G 418; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID DERIVATIVE; GENISTEIN; GENTAMICIN; MILRINONE; QUERCETIN; R 553X; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; W 1282X;

CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG STRUCTURE; GENE MUTATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0033557197     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6346     Document Type: Review

References (51)

1. Riordan, J.R., et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [erratum published Science. 245:1437]. Science. 245:1066-1073.
2. Rich, D.P., et al. 1991. Effect of deleting the R domain on CFTR-generated chloride channels. Science. 253:205-207.
3. Ma, J., et al. 1996. Phosphorylation-dependent block of cystic fibrosis transmembrane conductance regulator chloride channel by exogenous R domain protein. J. Biol. Chem. 271:7351-7356.
4. Schwiebert, E.M., et al. 1995. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell. 81:1063-1073.
5. Ismailov, I.I., et al. 1996. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 271:4725-4732.
6. Smith, J.J., Travis, S.M., Greenberg, E.P., and Welsh, M.J. 1996. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid [erratum published Cell. 87(2)]. Cell. 85:229-236.
7. Ashkenas, J., and Byers, P.H. 1997. The final stage of gene expression: chaperones and the regulation of protein fate. Am. J. Hum. Genet. 61:267-272.
8. Dalemans, W., et al. 1991. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation [see comments]. Nature. 354:526-528.
9. Howard, M., Frizzell, R.A., and Bedwell, D.M. 1996. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations [see comments]. Nat. Med. 2:467-469.
10. Shoshani, T., et al. 1994. Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells. J. Clin. Invest. 93:1502-1507.
11. Bedwell, D.M., et al. 1998. Aminoglycoside repair of premature translation termination mutations. Pediatr. Pulmonol. 17(Suppl.):168. (Abstr.)
12. Wilschanski, M., et al. 1998. Topical gentamicin rectifies abnormal nasal potential difference measurements in CF patients homozygous for STOP mutations. Pediatr. Pulmonol. 17(Suppl.):253. (Abstr.)
13. Denning, G.M., et al. 1992. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive [see comments]. Nature 358:761-764.
14. Ko, Y.H., Thomas, P.J., Delannoy, M.R., and Pedersen, P.L. 1993. The cystic fibrosis transmembrane conductance regulator. Overexpression, purification, and characterization of wild type and delta F508 mutant forms of the first nucleotide binding fold in fusion with the maltose-binding protein. J. Biol. Chem. 268:24330-24338.
15. Brown, C.R., Hong-Brown, L.Q., and Welch, W.J. 1997. Correcting temperature-sensitive protein folding defects. J. Clin. Invest. 99:1432-1444.
16. Egan, M.E., Schweibert, E.M., and Guggino, W.B. 1995. Differential expression of ORCC and CFTR induced by low temperature in CF airway epithelial cells. Am. J. Physiol. 268:C243-C251.
17. Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J., and Kopito, R.R. 1996. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271:635-638.
18. Jensen, T.J., et al. 1995. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell. 83:129-135.
19. Ward, C.L., and Kopito, R.R. 1994. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J. Biol. Chem. 269:25710-25718.
20. Ward, C.L., Omura, S., and Kopito, R.R. 1995. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell. 83:121-127.
21. Yang, Y., Janich, S., Cohn, J.A., and Wilson, J.M. 1993. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. USA. 90:9480-9484.
22. Pind, S., Riordan, J.R., and Williams, D.B. 1994. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269:12784-12788.
23. Strickland, E., Qu, B.H., Millen, L., and Thomas, P.J. 1997. The molecular chaperone hsc70 assists the in vitro folding of the N- terminal nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator [In Process Citation]. J. Biol. Chem. 272:25421-25424.
24. Pasyk, E.A. and Foskett, J.K. 1995. Mutant (delta F508) cystic fibrosis transmembrane conductance regulator Cl channel is functional when retained in endoplasmic reticulum of mammalian cells. J. Biol. Chem. 270:12347-12350.
25. Haws, C.M., et al. 1996. Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am. J. Physiol. 270:C1554-C1555.
26. Jiang, C., et al. 1998. Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am. J. Physiol. 275:C171-C178.
27. Cheng, S.H., et al. 1995. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am. J. Physiol. 268:L615-L624.
28. Rubenstein, R.C., Egan, M.E., and Zeitlin, P.L. 1997. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. 100:2457-2465.
29. Constantoulakis, P., Knitter, G., and Stamatoyannopoulos, G. 1989. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood. 74:1963-1971.
30. Perrine, S.P., et al. 1994. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. Am. J. Pediatr. Hematol. Oncol. 16:67-71.
31. Carducci, M., et al. 1998. Phenylbutyrate (PB) for refractory solid rumors: a phase I clinical and pharmacological evaluation. Proc. Am. Assoc. Cancer Res. 39:506.
32. Rubenstein, R.C., and Zeitlin, P.L. 1998. Sodium 4-phenylbutyrate promotes DF508-CFTR trafficking by down-regulation of HSC70. Pediatr. Pulmonol. 17(Suppl.):211. (Abstr.)
33. Rubenstein, R.C., and Zeitlin, P.L. 1998. A pilot clinical trial of sodium 4-phenylbutyrate (Buphenyl) in delta F508-homozygous cystic fibrosis patients: evidence of restoration of nasal epithelial CFTR function. Am. J. Resp. Crit. Care Med. 157:484-490.
34. Kemp, S., et al. 1998. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy [see comments]. Nat. Med. 4:1261-1268.
35. Brown, C.R., Hong-Brown, L.Q., and Welch, W.J. 1997. Strategies for correcting the delta F508 CFTR protein-folding defect. J. Bioenerg. Biomembr. 29:491-502.
36. Cohen, B.E., et al. 1997. 8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry. 36:6455-6461.
37. Guay-Broder, C., et al. 1995. A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry. 34:9079-9087.
38. Arispe, N., Ma, J., Jacobson, K.A., and Pollard, H.B. 1997. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-Cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-Diallyl-8-cyclohexylzanthine (DAX). J. Biol. Chem. 273:5727-5734.
39. Illek, B., Fischer, H., and Machen, T.E. 1998. II. Regulation of CFTR by small molecules including HCO-3. Am. J. Physiol. 275:G1221-G1226.
40. He, Z., Raman, S., Guo, Y., and Reenstra, W. 1998. Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms. Am. J. Physiol. 275:C958-C966.
41. Weinreich, F., Wood, P.G., Riordan, J.R., and Nagel, G. 1997. Direct action of genistein on CFTR. Pflugers Arch. 434:484-491.
42. Janssen, K., et al. 1998. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am. J. Clin. Nutr. 67:255-262.
43. Illek, B., and Fischer, H. 1998. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am. J. Physiol. 275:L90-L910.
44. Hwang, T.C., Wang, F., Yang, I.C., and Reenstra, W.W. 1997. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am. J. Physiol. 273:C988-C998.
45. Fischer, H., and Illek, B. 1998. Effects of genistein on disease-causing mutant CFTRs. Pediatr. Pulmonol. 17(Suppl.):239. (Abstr.)
46. Gondor, M., et al. 1998. Genistein stimulates chloride secretion in normal volunteers and CF patients with a G551D mutation. Pediatr. Pulmonol. 17(Suppl.):253. (Abstr.)
47. Smith, S.N., et al. 1998. Effect of IBMX and alkaline phosphatase inhibitors on Cl secretion in G551D cystic fibrosis mutant mice. Am. J. Physiol 274:C492-C499.
48. Hamosh, A., et al. 1991. Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J. Clin. Invest. 88:1880-1885.
49. Drumm, M.L., Steagall, W.K., Kelley, T.J., Milgram, L.J., and Konstan, M.W. 1998. Phosphodiesterase inhibitor-stimulated chloride secretion from gut and respiratory epithelia. Pediatr. Pulmonol. 17(Suppl.):168-169.
50. Knowles, M.R., Clarke, L.L., and Boucher, R.C. 1992. Extracellular ATP and UTP induce chloride secretion in nasal epithelia of cystic fibrosis patients and normal subjects in vivo. Chest. 101:60s-63s.
51. Zeitlin, P.L., Guggino, W.B., and Molina, L. 1998. Activation by the nonadecapeptide 2622U90 (Duramycin) of chloride secretion in healthy volunteers and patients with cystic fibrosis. Pediatr. Pulmonol. 17(Suppl.):277.